Elsadek, B <br/><br/>
In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).  [electronic resource] 

 -  Prostate cancer and prostatic diseases  Mar 2011 
 - 14-21 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5608 
<br/><br/><label>Standard No.: </label>10.1038/pcan.2010.43  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibiotics, Antineoplastic--metabolism<br/>Cell Line, Tumor<br/>Disease Models, Animal<br/>Doxorubicin--metabolism<br/>Humans<br/>Male<br/>Mice<br/>Mice, SCID<br/>Neoplasm Transplantation<br/>Prodrugs--metabolism<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--drug therapy<br/>Serum Albumin--metabolism<br/>Xenograft Model Antitumor Assays